Filing Analysis
Sanara MedTech Inc. reported the results of its Annual Meeting of Shareholders held on June 4, 2026. Shareholders approved the election of the Board of Directors, the ratification of the independent auditor, and executive compensation matters.
📋 Key Facts
- Annual Meeting held on June 4, 2026, with 6,701,593 shares represented.
- Nine directors were elected to the Board for one-year terms.
- Weaver and Tidwell, L.L.P. was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Shareholders approved executive compensation on an advisory basis.
- The company will now conduct advisory votes on executive compensation every three years, with the next vote expected in 2029.
Sanara MedTech Inc. has mutually terminated its Transaction Advisory Services Agreement with The Catalyst Group, Inc., effective June 2, 2026. The termination is attributed to a shift in corporate strategy toward soft tissue repair and bone fusion products.
🚩 Red Flags
- The agreement was a related-party transaction: The Company's Chairman, Ronald T. Nixon, is the founder and managing partner of The Catalyst Group, Inc.
- The Catalyst Group and its affiliates are significant shareholders, owning more than 5% of the Company's outstanding common stock.
📋 Key Facts
- The Services Agreement was originally effective as of March 1, 2023.
- The agreement was terminated via a Mutual Termination Agreement on June 2, 2026.
- No fee or penalty was paid by the Company to effectuate the termination.
- Indemnification and confidentiality covenants remain in effect.
- The Company is shifting its strategic focus to soft tissue repair and bone fusion products for the surgical market.
Sanara MedTech Inc. reported its financial results for the first quarter ended March 31, 2026. The results were disclosed via a press release furnished as Exhibit 99.1 to the filing.
📋 Key Facts
- The filing reports financial results for the fiscal quarter ended March 31, 2026.
- The report was filed on May 11, 2026, under Item 2.02 (Results of Operations and Financial Condition).
- The information in the report and the attached press release is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Sanara MedTech Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025. The results were disclosed via a press release furnished as an exhibit to the 8-K filing on March 24, 2026.
📋 Key Facts
- Reporting date of March 24, 2026, for the fiscal period ended December 31, 2025.
- The filing was made under Item 2.02 (Results of Operations and Financial Condition).
- Exhibit 99.1 contains the press release detailing the financial performance.
Sanara MedTech Inc. furnished an investor presentation in connection with its participation in the TD Cowen 46th Annual Health Care Conference. The presentation outlines the company's strategic priorities and provides anticipated revenue guidance for the 2026 fiscal year.
📋 Key Facts
- The company is presenting at the TD Cowen 46th Annual Health Care Conference in Boston on March 3, 2026.
- The filing includes an investor presentation as Exhibit 99.1.
- The presentation contains anticipated revenue figures for the 2026 fiscal year.
- The information is furnished under Item 7.01 and is not deemed 'filed' for purposes of Section 18 of the Exchange Act.